Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months

Pediatrics

Volumn 128, Issue 2, 2011, Pages

  Skowronski, Danuta M ^a   Hottes, Travis S ^a   Chong, Mei ^a   De Serres, Gaston ^b   Scheifele, David W ^c   Ward, Brian J ^d   Halperin, Scott A ^e   Janjua, Naveed Z ^a   Chan, Tracy ^a   Sabaiduc, Suzana ^a   Petric, Martin ^a  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MONTREAL GENERAL HOSPITAL   (Canada)

^e DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Child; Children; Dosage; Immunologic dose response relationship; Infants; Influenza; Influenza vaccine; Influenza vaccines administration; Influenza vaccines adverse effects; Influenza vaccines immunology; Randomized controlled trial

Indexed keywords

INFLUENZA VACCINE;

AGE DISTRIBUTION; ANOREXIA; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE SWELLING; ARTICLE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INJECTION SITE INDURATION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SLEEP DISORDER; TODDLER; TOOTH ERUPTION;

AGE FACTORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGENETICS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; VACCINES, INACTIVATED;

EID: 80051488590     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-2777     Document Type: Article

References (42)

1. Coffin SE, Zaoutis TE, Rosenquist AB, et al. Incidence, complications, and risk factors for prolonged stay in children hospitalization with community-acquired influenza. Pedatrics. 2007;119(4):740-748 (Pubitemid 46556673)
2. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med. 2000;342(4):232-239 (Pubitemid 30058954)
3. Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000;342(4):225-231 (Pubitemid 30058953)
4. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2004;53(RR-8):1-40
5. National Advisory Committee on Immunization (NACI). Statement on influenza vaccination for the 2004-2005 season. Can Commun Dis Rep. 2004;30:1-32
6. UK Department of Health. Immunization against infectious disease. In: Salisbury D, Ramsay M, and Noakes K, eds. The Green Book. London, United Kingdom: The Stationary Office; 2006:185-200
7. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-8):1-62
8. National Advisory Committee on Immunization (NACI). Statement on seasonal trivalent inactivated influenza vaccine (TIV) for 2010-2011. Can Commun Dis Rep. 2010;36(ACS-6):1-49
9. Kilbourne ED, Arden NH. Inactivated influenza vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia, PA: WB Saunders Company; 1999:531-551
10. Ruben FL. Influenza virus vaccines in children. Clin Infect Dis. 2004;38(5):678-688
11. Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J. 2001;20(8):733-740 (Pubitemid 32758013)
12. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356(7):685-696
13. Rosenberg M, Sparks R, McMahon A, Iskander J, Campbell JD, Edwards KM. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age. Vaccine. 2009;27(32):4278-4283
14. Skowronski DM, Jacobsen K, Daigneault J, et al. Solicited adverse events after influenza immunization among infants, toddlers, and their household contacts. Pediatrics. 2006;117(6):1963-1971 (Pubitemid 46071240)
15. Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics. 2005;115(4):1039-1047
16. Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics. 2006;118(3). Available at: www.pediatrics.org/cgi/ content/full/118/3/e579
17. Hoberman A, Greenberg DP, Paradise JL, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA. 2003;290(12):1608-1616 (Pubitemid 37430385)
18. Mitchell DK, Ruben FL, Gravenstein S. Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004. Pediatr Infect Dis J. 2005;24(10):925-927 (Pubitemid 41475932)
19. Walter EB, Neuzil KM, Zhu Y, et al. Influenza vaccine immunogenicity in 6- to 23-monthold children: are identical antigens necessary for priming? Pediatrics. 2006;118 (3). Available at: www.pediatrics.org/cgi/content/full/118/ 3/e570
20. Walter EB, Rajagopal S, Zhu Y, Neuzil KM, Fairchok MP, Englund JA. Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally? Vaccine. 2010;28(27):4376-4383
21. Wright PF, Sannella E, Shi JR, Zhu Y, Ikizler MR, Edwards KM. Antibody responses after inactivated influenza vaccine in young children. Pediatr Infect Dis J. 2008;27(11):1004-1008
22. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2008;(2):CD004879
23. Centers for Disease Control and Prevention. Update: influenza activity: United States and worldwide, 2003-04 season, and composition of the 2004-05 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2004;53(25):547-552
24. Szilagyi PG, Fairbrother G, Griffin MR, et al. Influenza vaccine effectiveness among children 6 to 59 months of age during 2 influenza seasons. Arch Pediatr Adolesc Med. 2008;162(10):943-951
25. Eisenberg KW, Szilagyi PG, Fairbrother G, et al. Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003 2004 and 2004 2005 influenza seasons. Pedatrics. 2008;122(5):911-919
26. Shuler CM, Iwamoto M, Bridges CB, et al. Vaccine effectiveness against medically attended, laboratory-confirmed influenza among children aged 6 to 59 months, 2003-2004. Pediatrics. 2007;119(3). Available at: www.pediatrics.org/ cgi/content/full/119/3/e587
27. Allison MA, Daley MF, Crane LA, et al. Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 season. J Pediatr. 2006;149(6):755-762
28. Ritzwoller DP, Bridges CB, Shetterly S, Yamasaki K, Kolczak M, France EK. Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pedatrics. 2005;116(1):153-159
29. Gross PA, Ennis FA, Noble GR, Gaerlan PF, Davis WJ, Denning CE. Influenza vaccine in unprimed children: improved immunogenicity with few reactions following one high dose of split-product vaccine. Pediatrics. 1980;97(1):56-60 (Pubitemid 10033763)
30. Gross PA, Quinnan GV, Gaerlan PF, et al. Potential for single high-dose influenza immunization in unprimed children. Pediatrics. 1982;70(6):982-986 (Pubitemid 13247257)
31. Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity of a high dose trivalent influenza vaccine among elderly subjects. Vaccine. 2007;25(44):7656-7663 (Pubitemid 47554468)
32. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med. 2006;166(10):1121-1127 (Pubitemid 43765184)
33. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonization of requirementsforinfluenzavaccines.London,UK: European Agency for the Evaluation of Medicinal Products [article online], 1997. CPMP/BWP/214/96 (circular 96-0666):1-22. Available at: www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003945.pdf. Accessed July 28, 2010
34. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull. 1979;35(1):69-75 (Pubitemid 9096975)
35. Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med. 2005;353(24):2559-2567 (Pubitemid 41785893)
36. Engler RJM, Nelson MR, Klote MM et al. Halfvs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose and sex effects on immune responses. Arch Intern Med. 2008;168(22):2405-2414
37. Treanor J, Keitel W, Belshe R et al. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine. 2002;20(7-8):1099-1105 (Pubitemid 34135945)
38. Monto AS., Maassab F. Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test. J Clin Microbiol. 1981;13(1):54-57 (Pubitemid 11176658)
39. Kendal AP, Cate TR. Increased sensitivity and reduced specificity of hemagglutination inhibition tests with ether-treated influenza B/Singapore/222/79. J Clin Microbiol. 1983;18(4):930-934
40. de Jong JC, Palache AM, Beyer WEP, Rimmelzwaan GF, Boon ACM, Osterhaus ADME. Haemagglutination-inhibiting antibody to influenza virus. In: Brown F, Haaheim LR, Schild GC, eds. Laboratory Correlates of Immunity to Influenza: A Reassessment - Developments in Biologicals. Vol 115, Basel, Switzerland: Karger; 2003:63-73
41. Ansaldi F, Bacilieri S, Banfi F, et al. Neutralizing and hemagglutination-inhibiting activities of antibodies elicited by the 2004-2005 influenza vaccine against drifted viruses. Clin Vaccine Immunol. 2006;13(1):162-164
42. Public Health Agency of Canada. FluWatch weekly reports 2008-09 season. Available at: www.phac-aspc.gc.ca/fluwatch/08-09/index-eng.php. Accessed September 13, 2010